title: Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events.
abstract: The growth of rat hepatoma 7288CTC in vivo is stimulated by the uptake of linoleic acid (LA) and its metabolism to 13-hydroxyoctadecadienoic acid (13-HODE), an important mitogenic signaling molecule within this tumor. Conversely, the growth of a variety of experimental cancers in vivo is inhibited by either physiological or pharmacological levels of the pineal gland hormone melatonin, although the mechanism(s) are unknown. We tested the hypothesis that the mechanism of melatonin's anticancer action in vivo involves the inhibition of tumor LA uptake and metabolism to 13-HODE in hepatoma 7288CTC. Tumor uptake of LA and release of 13-HODE, measured in tissue-isolated rat hepatoma 7288CTC at 4-h intervals over a 24-h period, were highest during the light phase and lowest during the mid-dark phase, when plasma melatonin levels were lowest and highest, respectively. Pinealectomy eliminated this rhythm of tumor LA uptake and 13-HODE production, indicating that it was driven by the circadian melatonin rhythm. Perfusion of tissue-isolated tumors in situ with melatonin (1 nM) rapidly and reversibly inhibited the uptake of plasma fatty acids (FAs), including LA, and its metabolism to 13-HODE. These inhibitory effects of melatonin on tumor FA uptake and 13-HODE release were completely reversed by perfusion of tumors in situ with melatonin receptor antagonist S-20928, pertussis toxin, forskolin, or 8-bromo-cAMP. Perfusion of tumors in situ with melatonin also decreased tumor [3H]thymidine incorporation and DNA content; these effects on DNA synthesis were also prevented by the coperfusion of tumors with melatonin and S-20928, pertussis toxin, forskolin, 8-Br-cAMP, or 13-HODE. Pinealectomy stimulated tumor growth, LA uptake and metabolism to 13-HODE, and FA storage in hepatoma 7288CTC, whereas melatonin administration (200 microg/day) was inhibitory in vivo. Northern blot analysis revealed that, compared with normal liver tissue, hepatoma 7288CTC overexpressed mRNA transcripts for a plasma membrane-associated FA transport protein (FATP). FATP mRNA expression was unaffected by the treatment of tumor-bearing rats with daily afternoon melatonin injections or exposure to constant light. These results support a novel mechanism of tumor growth inhibition by melatonin involving a melatonin receptor-mediated suppression of cAMP levels, resulting in diminished tumor FA transport, possibly via decreased FATP function. The inhibition of these signal transduction events by melatonin culminates in the suppression of LA uptake, LA metabolism to the mitogenic signaling molecule 13-HODE, and cancer growth.
authors.affiliation: Laboratory of Experimental Neuroendocrinology/Oncology, Bassett Research Institute, Cooperstown, New York 13326-1394, USA. dblask@usa.net
authors.forename: D E
authors.initials: DE
authors.lastname: Blask
authors.forename: L A
authors.initials: LA
authors.lastname: Sauer
authors.forename: R T
authors.initials: RT
authors.lastname: Dauchy
authors.forename: E W
authors.initials: EW
authors.lastname: Holowachuk
authors.forename: M S
authors.initials: MS
authors.lastname: Ruhoff
authors.forename: H S
authors.initials: HS
authors.lastname: Kopff
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002940:Circadian Rhythm; D005576:Colforsin / Q000494:pharmacology; D019787:Linoleic Acid / Q000378:metabolism*; D008041:Linoleic Acids / Q000378:metabolism* / Q000494:pharmacology; D008114:Liver Neoplasms, Experimental / Q000473:pathology* / Q000503:physiopathology*; D008297:Male; D008550:Melatonin / Q000494:pharmacology*; D008954:Models, Biological; D009281:Naphthalenes / Q000494:pharmacology; D010477:Perfusion; D037342:Pertussis Toxin; D051381:Rats; D011915:Rats, Inbred BUF; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors / Q000502:physiology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors / Q000502:physiology*; D044094:Receptors, Melatonin; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
chemical_list: D008041:Linoleic Acids; D009281:Naphthalenes; D011956:Receptors, Cell Surface; D018160:Receptors, Cytoplasmic and Nuclear; D044094:Receptors, Melatonin; D010566:Virulence Factors, Bordetella; C106874:N-(2-(1-naphthalenyl)ethyl)cyclobutanecarboxamide; D005576:Colforsin; D015124:8-Bromo Cyclic Adenosine Monophosphate; C024348:13-hydroxy-9,11-octadecadienoic acid; D019787:Linoleic Acid; D037342:Pertussis Toxin; D008550:Melatonin